Heparan sulfate proteoglycan syndecan-1, CD138, is well known to be associated with cell proliferation, adhesion, and migration in various types of
malignancies. In the present study, we focused on the role of
syndecan-1 in human urothelial
carcinoma of the urinary bladder. Silencing of
syndecan-1 by
siRNA transfection down-regulated transcriptional factor junB and the long
isoform of
FLICE-inhibitory protein (FLIP long), resulting in the induction of apoptosis in the urothelial
carcinoma cell lines UMUC2 and UMUC3. Knockdown of junB and FLIP long as well as
syndecan-1 silencing mediated apoptosis that was inhibited by pan-
caspase inhibitors. Transurethral injection of
syndecan-1 siRNA into the urinary bladder significantly reduced
syndecan-1 gene expression and growth of red fluorescent-labeled KU-7/RFP
bladder cancer cells in the mouse orthotopic
bladder cancer model. Immunohistochemical examination showed high
syndecan-1 protein expression in high-grade, superficial, and deep invasive
carcinomas (pT1 and >or=pT2) as well as
carcinoma in situ, but not in low-grade and noninvasive phenotypes (pTa). In addition, the percentage of
cancer cells positive for
syndecan-1 at initial diagnosis was statistically associated with the frequency of
bladder cancer recurrence after transurethral resection. In conclusion,
syndecan-1 might contribute to urothelial
carcinoma cell survival and progression; therefore, this molecule could be a new therapeutic target in human
urinary bladder cancer.